<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">The first reported inhibitors were covalently binding peptidomimetics (
 <bold>1</bold>–
 <bold>3</bold>) addressing the major substrate-recognition motif from 
 <italic>P</italic>
 <sub>1</sub>′ to 
 <italic>P</italic>
 <sub>3</sub>.
 <xref rid="b0295" ref-type="bibr">
  <sup>59</sup>
 </xref> They all comprise an α-ketoamide functionality that forms a hemithioacetal with Cys145. α-Ketoamides are already used as viral serine protease warheads in the approved HCV drugs telaprevir and boceprevir.
 <xref rid="b0310" ref-type="bibr">
  <sup>62</sup>
 </xref> Compound 
 <bold>1</bold> has previously been investigated as a broad-spectrum corona- and enteroviral protease inhibitor.
 <xref rid="b0300" ref-type="bibr">
  <sup>60</sup>
 </xref> Like many other M
 <sup>pro</sup> inhibitors, the 
 <italic>P</italic>
 <sub>1</sub> side chains of 
 <bold>1</bold>–
 <bold>3</bold> employ a γ-lactam as a glutamine mimetic. 
 <italic>P</italic>
 <sub>2</sub> comprises hydrophobic cyclohexyl (
 <bold>1</bold>, 
 <bold>2</bold>) or smaller cyclopropyl (
 <bold>3</bold>) groups as leucine mimetics and 
 <italic>P</italic>
 <sub>1</sub>′ contains cyclopropyl (
 <bold>2</bold>) or benzyl (
 <bold>1</bold>, 
 <bold>3</bold>) residues. Compounds 
 <bold>2</bold> and 
 <bold>3</bold> feature pyridone rings between 
 <italic>P</italic>
 <sub>2</sub> and 
 <italic>P</italic>
 <sub>3</sub> as well as 
 <italic>N</italic>-terminal Boc groups, which were associated with increased plasma half-life, kinetic solubility and thermodynamic solubility. Pharmacokinetic profiling of 
 <bold>2</bold> and 
 <bold>3</bold> in mice also indicated favourable lung tropism. Compounds 
 <bold>1</bold> and 
 <bold>3</bold> displayed sub-micromolar M
 <sup>pro</sup> inhibition (
 <xref rid="f0035" ref-type="fig">Fig. 7</xref> ). Compound 
 <bold>3</bold> is similarly active against the SARS-CoV and MERS-CoV main proteases and inhibits SARS-CoV-2 replication in human Calu3 lung cells.
</p>
